May 9, 2023
FDA extends approval of Dapagliflozin
Based on the positive results from the DELIVER Phase III trial, the FDA has extended approval of dapagliflozin to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure (HF) visits in adults with HF.
Dec 24, 2022
AHA includes DELIVER in top advances in cardiovascular disease in 2022
The American Heart Association recognizes DELIVER and the SGLT2 meta-analysis in the top cardiovascular research of 2022